Armistice Capital LLC is a New York-based hedge fund that specializes in value-oriented and event-driven investment strategies. The firm primarily focuses on opportunities within the health care and consumer sectors, employing a disciplined approach to identify and capitalize on undervalued assets. Armistice Capital emphasizes a thorough analysis of market trends and company fundamentals to drive investment decisions, aiming to deliver significant returns for its clients.
Adocia is a clinical-stage biotechnology company based in Lyon, France, founded in 2005 and initially named Proteins & Peptides Management S.A.S. It focuses on the development of innovative formulations of approved therapeutic proteins and peptides to treat diabetes and other metabolic diseases. The company utilizes its proprietary Biochaperone technology platform, which enhances the efficacy of these therapeutic agents. Adocia's clinical pipeline features products like Biochaperone Lispro, Biochaperone Combo, and Biochaperone Glucagon, while its pre-clinical pipeline includes BioChaperone LisPram and BioChaperone Glargine GLP-1, among others. Additionally, the company holds a patent portfolio that encompasses chronic wound healing, insulin therapy, and monoclonal antibodies.
ProMIS Neurosciences
Post in 2024
ProMIS Neurosciences is a development-stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular, Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). It was founded in 2004 and headquartered in Toronto, Canada.
Assembly Biosciences
Post in 2024
Assembly Biosciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing innovative therapies for hepatitis B virus (HBV) infection and microbiome-related disorders. The company's HBV program is advancing multiple oral therapeutic candidates aimed at improving cure rates for chronic HBV by targeting various stages of the viral lifecycle through core protein inhibitors. Concurrently, its microbiome program employs a comprehensive platform that includes strain identification, isolation, and a patented delivery system, GEMICEL, for targeted oral delivery of therapeutics to the lower gastrointestinal tract. This program is developing novel oral biotherapeutics to address conditions such as Crohn's disease and C. difficile infections. Assembly has established collaboration agreements with Allergan Pharmaceuticals and Door Pharmaceuticals to further develop its microbiome and HBV programs, respectively. Since its inception in 2005, the company has evolved from its previous identity as Ventrus Biosciences, Inc., reflecting its commitment to advancing impactful treatments in the biotechnology sector.
Corvus Pharmaceuticals
Post in 2024
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company based in Burlingame, California, dedicated to developing innovative immuno-oncology therapies. The company’s lead product candidate, Ciforadenant (CPI-444), is an oral small molecule antagonist of the A2A receptor and is currently undergoing Phase Ib/2 clinical trials. Additionally, Corvus is advancing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib trials aimed at inhibiting adenosine production and stimulating immune responses, as well as investigating its potential for treating COVID-19. Another candidate, CPI-818, is a small molecule that selectively inhibits interleukin-2-inducible T-cell kinase and is also in Phase I/Ib trials. Corvus Pharmaceuticals collaborates strategically with Angel Pharmaceuticals to enhance its pipeline of targeted investigational medicines. Founded in 2014, the company is focused on addressing significant unmet medical needs in cancer treatment and related diseases.
Zura Bio
Post in 2024
Zura Bio is a clinical-stage biotechnology company that develops innovative therapies for immune and inflammatory disorders. The company focuses on advancing its programs through phase 2 development, specifically targeting auto-immune illnesses. One of its key assets, ZB-168, is an anti-IL7R inhibitor designed to address disorders linked to the biological pathways of IL7 and TSLP, building on data from phase 1b studies related to type 1 diabetes. Additionally, Zura Bio is progressing the phase 2 clinical development of torudokimab, a human-affinity monoclonal antibody that neutralizes IL33. Through these efforts, Zura Bio aims to create effective therapeutic solutions for patients suffering from various immune-related conditions.
ARTARA THERAPEUTICS
Post in 2024
ARTARA THERAPEUTICS is a clinical-stage healthcare company focused on developing transformative therapies for individuals with rare and specialty diseases. Its lead program, TARA-002, is an investigational cell therapy designed to treat lymphatic malformations and non-muscle invasive bladder cancer. Additionally, the company is advancing intravenous choline chloride, an investigational phospholipid substrate replacement therapy aimed at addressing intestinal failure-associated liver disease. Based in New York, ARTARA THERAPEUTICS is dedicated to providing innovative solutions for patients with limited treatment options, leveraging a team that values creativity and diverse perspectives to expedite the development of its therapies.
CervoMed
Post in 2024
CervoMed is a clinical-stage company focused on developing therapeutic treatments for neurodegenerative diseases, particularly in the early stages of these illnesses. The firm specializes in creating drugs aimed at addressing conditions affecting the central nervous system, with a primary emphasis on Alzheimer's disease. CervoMed's innovative approach includes a drug that promotes functional recovery in patients experiencing acute neurological injuries, thereby enhancing the ability of healthcare professionals to effectively manage brain diseases and improve episodic memory functions in affected individuals.
Greenidge Generation Holdings
Post in 2024
Greenidge is a 106MW natural gas power plant and blockchain mining facility. Greenidge Generation has been transformed into a power plant for the twenty-first century. In January 2020, Greenidge launched the first phase of a data center for blockchain mining. Greenidge was established in 1937 and is based in Dresden, New York, United States.
Tenaya Therapeutics
Post in 2024
Tenaya Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs three main platforms to address the underlying causes of heart disease: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads, and a precision medicine approach tailored to individual patients. Through these platforms, Tenaya Therapeutics aims to enable the regeneration of heart tissue and tackle various forms of cardiomyopathies, leveraging advanced research in cardiac development and regeneration.
Outlook Therapeutic
Post in 2024
Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company based in Cranbury, New Jersey, specializing in the development and commercialization of monoclonal antibodies for ophthalmic conditions. The company's primary product candidate, ONS-5010, is a proprietary formulation of bevacizumab currently undergoing Phase-III clinical trials aimed at treating wet age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion, among other retinal diseases. Outlook Therapeutics has established collaboration and license agreements with several partners, including IPCA Laboratories Limited and Laboratorios Liomont, among others. Originally incorporated in 2010 as Oncobiologics, the company rebranded to its current name in November 2018 to better reflect its focus on ophthalmic therapeutics.
Aligos Therapeutics
Post in 2023
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company specializes in developing innovative therapeutics to address unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). Its lead drug candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for CHB. Aligos is also advancing several other candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist for NASH. The company's strategy leverages the extensive expertise of its team in liver disease and viral hepatitis to develop targeted antiviral therapies and expedite its drug development pipeline.
Mithra Pharmaceuticals
Post in 2023
Mithra Pharmaceuticals SA develops, manufactures, and markets innovative therapeutics focused on women's health, particularly in the areas of contraception, menopause, and hormone-dependent cancers. The company's key development candidates include Estelle, a fifth-generation oral contraceptive that has completed phase III clinical trials, and Donesta, a next-generation hormone therapy for menopausal symptoms currently in phase III trials. Additionally, Mithra is advancing several other products, such as Myring, a contraceptive vaginal ring, and Zoreline, a biodegradable implant for treating prostate and breast cancers. Established in 1999 and headquartered in Liège, Belgium, Mithra Pharmaceuticals operates in multiple regions, including Belgium, Europe, and beyond, and offers a comprehensive spectrum of services through its CDMO, catering to research, development, and specialist manufacturing needs.
COMPASS Pathways
Post in 2023
COMPASS Pathways is a mental health care company based in Cheshire, United Kingdom, with operations in the United States. The company is focused on developing innovative therapies for treatment-resistant depression (TRD) using its proprietary psilocybin formulation, COMP360. Currently undergoing Phase IIb clinical trials, COMP360 aims to provide a new treatment option for patients who have not responded to traditional depression therapies. COMPASS Pathways emphasizes the combination of psilocybin-assisted therapy with psychological support to enhance treatment efficacy. The company is committed to addressing the significant unmet needs in mental health care by advancing evidence-based solutions for those suffering from mental health challenges.
Lyra Therapeutics
Post in 2023
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.
Spruce Biosciences
Post in 2023
Spruce Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare endocrine disorders, particularly those affecting the hypothalamic-pituitary-adrenal axis. Founded in 2014 and headquartered in Daly City, California, the company is advancing its lead product candidate, tildacerfont, which is currently undergoing Phase IIb clinical trials for adult patients and Phase II clinical trials for children with classic congenital adrenal hyperplasia (CAH). Tildacerfont is positioned as a potential first non-steroidal therapy that aims to improve disease control and reduce the reliance on steroids for patients with CAH. Additionally, Spruce is exploring the use of tildacerfont for women with polycystic ovary syndrome. The company has also entered into a licensing agreement with Eli Lilly and Company to research and develop compounds for various pharmaceutical applications.
Karyopharm Therapeutics
Post in 2022
Karyopharm Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Newton, Massachusetts, specializing in the discovery, development, and commercialization of novel drugs targeting nuclear export mechanisms for the treatment of cancer and other diseases. Its lead drug, XPOVIO (selinexor), is an approved treatment for multiple hematologic malignancies, particularly in patients with heavily pretreated multiple myeloma. The company is advancing several clinical trials for its products, including BOSTON and STORM for multiple myeloma, SADAL for relapsed or refractory diffuse large B-cell lymphoma, and SEAL for liposarcoma. Karyopharm is also exploring treatments for endometrial cancer and glioblastoma multiforme. Additionally, the company has partnerships to investigate low-dose selinexor for hospitalized COVID-19 patients and collaborates with the National Cancer Institute for cancer therapy evaluations. Karyopharm utilizes a proprietary platform to develop small molecule drugs that modulate key cellular pathways involved in cancer and inflammation.
Abeona Therapeutics
Post in 2022
Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops therapies for Batten disease, cystic fibrosis, and genetic eye disorders. Additionally, Abeona Therapeutics is advancing the AIM Vector Platform, which includes over 100 next-generation AAV capsids for delivering gene therapies to various organs. The company operates a manufacturing facility producing therapies and vectors for preclinical and clinical studies.
Provention Bio
Post in 2022
Provention Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics aimed at intercepting and preventing immune-mediated diseases. The company's product candidates include PRV-031, a monoclonal antibody currently in Phase III clinical trials for the interception of type 1 diabetes, and PRV-6527, an oral CSF-1R inhibitor in Phase IIa trials for Crohn's disease. Additionally, PRV-3279 has completed Phase 1b trials for lupus, while PRV-101 is being developed as a vaccine for coxsackie virus B infections, which may prevent the onset of type 1 diabetes. Provention Bio also has a licensing agreement with Amgen for PRV-015, a monoclonal antibody targeting celiac disease. Founded in 2016 and based in Oldwick, New Jersey, Provention Bio aims to address the high morbidity and costs associated with chronic autoimmune and inflammatory diseases through its innovative predictive and preventive therapeutic approaches.
Eyenovia
Post in 2022
Eyenovia, Inc. is a clinical stage ophthalmic biopharmaceutical company based in New York, focused on developing innovative microdose therapeutics through its proprietary piezo-print delivery technology known as the Optejet. The company's aim is to enhance the delivery of ophthalmic pharmaceuticals by replacing traditional eye dropper methods, thereby improving safety, tolerability, and patient compliance for various eye treatments. Eyenovia's product pipeline includes several candidates: MicroLine, currently in Phase III development for presbyopia; MicroProst, also in Phase III trials for chronic angle closure glaucoma and ocular hypertension; MicroStat, which has completed Phase III trials for mydriasis; MicroTears for red eye and itch relief; and MicroPine for progressive myopia. The company seeks to address indications that lack FDA-approved drug therapies and was established in 2014, originally as PGP Holdings V, Inc., before rebranding to Eyenovia.
Xeris Biopharma Holdings
Post in 2022
Xeris Biopharma Holdings is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for patients in endocrinology, neurology, and gastroenterology. The company utilizes its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectables that facilitate subcutaneous and intramuscular delivery of various therapeutic agents. Xeris offers three commercially available products: Gvoke, a liquid glucagon for severe hypoglycemia; Keveyis, the first FDA-approved treatment for primary periodic paralysis; and Recorlev, approved for endogenous hypercortisolemia in adults with Cushing's Syndrome. Xeris Biopharma's formulation platforms aim to improve patient and caregiver ease of use by eliminating reconstitution, ensuring long-term stability at room temperature, and reducing injection volume, thereby enhancing healthcare delivery and potentially lowering costs for the healthcare system. The company is also advancing a pipeline of development programs to expand its product offerings.
erytech
Post in 2021
ERYtech Pharma specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.
Mauna Kea Technologies
Post in 2021
Mauna Kea Technologies is a global medical device company dedicated to enhancing the diagnosis and treatment of cancer and other diseases through real-time in vivo microscopic visualization. Its primary product, Cellvizio®, is an advanced imaging platform that enables optical biopsies, allowing physicians to examine tissues at a cellular level during standard medical procedures. This technology aids in the early detection of pathologies and informs therapeutic decisions. The company markets Cellvizio products and accessories for medical diagnostics and research in France and over 40 countries worldwide, generating revenue primarily from these sales.
Kiora Pharmaceuticals
Post in 2021
Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative treatments for ophthalmic diseases. The company's lead product, KIO-301, is a molecular photoswitch designed to restore light perception and improve vision in patients suffering from inherited and age-related retinal degeneration, including conditions such as retinitis pigmentosa, choroideremia, and Stargardt disease. Kiora is also developing KIO-101, a next-generation non-steroidal, immuno-modulatory small molecule inhibitor targeting dihydroorotate dehydrogenase, aimed at minimizing off-target side effects while effectively managing immune responses. Additionally, Kiora is working on KIO-201, a modified form of hyaluronic acid intended to promote corneal wound healing. Through these products, Kiora Pharmaceuticals seeks to address significant unmet medical needs in the ophthalmic space.
Medigus
Post in 2014
Medigus Ltd. is a medical device company based in Omer, Israel, focused on developing, manufacturing, and marketing minimally invasive endo-surgical tools and direct visualization technology. Founded in 1999, the company is known for its flagship product, the Medigus Ultrasonic Surgical Endostapler (MUSE) system, which provides a single-use device for the incisionless treatment of gastroesophageal reflux disease (GERD). This innovative system integrates a miniaturized video camera, a surgical stapler, and ultrasonic alignment technology, enabling gastroenterologists and surgeons to perform endoluminal procedures that eliminate the need for traditional open or laparoscopic surgery. In addition to its GERD treatment solutions, Medigus designs and manufactures advanced endoscopy systems and micro video cameras for various medical and industrial applications, leveraging its proprietary technologies to support a wide range of endoscopic procedures.
Addex Therapeutics
Post in 2013
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, that specializes in the discovery, development, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. The company primarily focuses on allosteric modulators, a novel class of orally available drugs that interact with G-protein coupled receptors, potentially offering advantages over traditional therapeutic approaches. Its lead product candidates include Dipraglurant for treating Parkinson's disease-related dyskinesia and dystonia, ADX71149 for epilepsy and other CNS disorders, and GABAB PAM for addiction. Addex has established a collaboration with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds aimed at addressing various health issues. Founded in 2002, Addex Therapeutics continues to advance its innovative drug discovery platform to improve therapeutic outcomes for patients with neurological conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.